How should hereditary hemochromatosis be diagnosed and managed, including iron overload criteria, first‑line phlebotomy protocol, alternative chelation therapy, monitoring, and family screening?

Hereditary Hemochromatosis: Diagnosis and Management

Diagnostic Approach

Begin with simultaneous measurement of fasting transferrin saturation (TS) and serum ferritin—these two tests together provide the highest diagnostic accuracy and should never be ordered separately. 1, 2

Initial Laboratory Thresholds

• Transferrin saturation ≥45% is the most sensitive early marker and the primary threshold triggering further evaluation 1, 2
• Serum ferritin thresholds: >300 μg/L in men or >200 μg/L in women indicate abnormal iron stores requiring investigation 1, 2
• Calculate TS as: (serum iron ÷ total iron-binding capacity) × 100 2

When to Proceed to Genetic Testing

If either TS ≥45% OR ferritin exceeds sex-specific thresholds, immediately order HFE mutation analysis for C282Y and H63D variants. 1, 2

Exclude Secondary Causes First

Before attributing elevated iron studies to hereditary hemochromatosis, rule out 1:

• Chronic alcohol consumption (check AST, ALT, GGT)
• Inflammatory conditions (check CRP, ESR)
• Cell necrosis (check AST, ALT, CK)
• Malignancy (CT scan if indicated)
• Non-alcoholic fatty liver disease/metabolic syndrome (check blood pressure, BMI, cholesterol, triglycerides, glucose)

Genetic Interpretation

• C282Y homozygosity (C282Y/C282Y) confirms HFE-related hemochromatosis and accounts for 85-90% of clinically affected patients 1, 2, 3
• Diagnosis requires BOTH genetic confirmation AND evidence of increased iron stores—do not diagnose based on C282Y homozygosity alone 1
• C282Y/H63D compound heterozygotes or H63D homozygotes with elevated iron parameters require investigation for other causes of hyperferritinemia before attributing to hemochromatosis 1, 2

Assessment for Advanced Disease and Organ Damage

Liver Disease Stratification

Order liver enzymes (ALT, AST) and platelet count immediately in all patients with confirmed iron overload. 2, 4

Liver biopsy is indicated if ANY of the following are present: 1, 2, 5

• Serum ferritin >1,000 μg/L
• Elevated ALT or AST
• Hepatomegaly on examination
• Age >40 years in C282Y homozygotes
• Platelet count <200 × 10⁹/L

Key prognostic rule: Ferritin >1,000 μg/L combined with elevated transaminases and platelets <200 predicts cirrhosis in approximately 80% of C282Y homozygotes. 2, 4, 5

Conversely, ferritin <1,000 μg/L reliably excludes cirrhosis regardless of genotype. 2

Cardiac Assessment

In patients with ferritin >1,000 μg/L or any cardiac symptoms, obtain ECG and echocardiography to screen for arrhythmias and cardiomyopathy. 4, 5, 6

Cardiac MRI for myocardial iron quantification is indicated in: 2, 4

• Juvenile hemochromatosis
• Signs or symptoms of heart disease
• Severe iron overload with cardiac dysfunction

Additional Organ Evaluation

Screen for common complications 4, 5:

• Diabetes mellitus: fasting glucose or HbA1c
• Arthropathy: particularly 2nd and 3rd metacarpophalangeal joints (86.5% of patients report joint symptoms) 4
• Hypogonadism: testosterone, LH, FSH in men
• Thyroid dysfunction: TSH

First-Line Treatment: Therapeutic Phlebotomy

Initiate therapeutic phlebotomy immediately in C282Y homozygotes with elevated iron stores—do not wait for liver biopsy. 4, 7, 6

Induction Phase Protocol

• Remove 1 unit (450-500 mL) of blood weekly until serum ferritin reaches 10-20 μg/L 7, 6, 8
• Monitor hemoglobin/hematocrit before each phlebotomy to ensure tolerance
• Check serum ferritin every 10-12 phlebotomies 2
• Target ferritin <50 μg/L during induction 4, 9

Maintenance Phase Protocol

• Maintain serum ferritin at 50-100 μg/L through periodic phlebotomy 4, 7, 6, 9
• Typical maintenance frequency: every 2-4 months 4
• Continue lifelong monitoring and phlebotomy 8

Contraindications to Phlebotomy

Phlebotomy is not appropriate in 6:

• Anemic patients (secondary iron-overload disorders such as thalassemia or sideroblastic anemia)
• Severe congestive heart failure

Alternative Therapy: Iron Chelation

Iron chelation therapy is the treatment of choice when phlebotomy is contraindicated: 6

• Patients with anemia and iron overload
• Severe congestive heart failure precluding blood removal
• Inability to tolerate phlebotomy

Monitoring Strategy

During Induction Phase

• Hemoglobin/hematocrit before each weekly phlebotomy
• Serum ferritin every 10-12 phlebotomies 2
• Continue until ferritin 10-20 μg/L achieved 7, 6

During Maintenance Phase

• Serum ferritin every 2-4 months 4
• Adjust phlebotomy frequency to maintain ferritin 50-100 μg/L 4, 9

Surveillance for Complications

• Patients with cirrhosis require hepatocellular carcinoma screening with ultrasound and AFP every 6 months 3
• Annual monitoring for diabetes, cardiac function, and endocrine abnormalities in established disease

Family Screening Protocol

All first-degree relatives (siblings, children, parents) of confirmed cases must undergo screening. 1, 2, 5

Recommended Screening Strategy

Perform simultaneous HFE genetic testing AND phenotypic screening (TS + ferritin) in a single visit. 2, 5

• For siblings: full genetic and phenotypic testing
• For children: test the other parent first; if the parent is genetically normal, the child is an obligate heterozygote and requires no further evaluation 2

Pre-Test Genetic Counseling

Before ordering genetic testing, discuss 2, 5:

• Efficacy of phlebotomy treatment
• Costs of testing and lifelong monitoring
• Potential insurance and employment implications
• Psychological impact of disease labeling
• Necessity of family screening
• Possibility of uncertain or variant genotypes

Dietary Management

Specific dietary restrictions include: 7

• Avoid medicinal iron and mineral supplements
• Avoid excess vitamin C supplementation (accelerates iron mobilization)
• Avoid uncooked seafood (risk of Vibrio vulnificus infection in iron-overloaded patients)
• Alcohol avoidance (increases hepatotoxicity)

General dietary iron restriction is not necessary and does not significantly impact treatment 3

Common Pitfalls and Caveats

Diagnostic Errors

• Never use ferritin alone for screening—it can be falsely elevated by inflammation, liver disease, malignancy, or metabolic syndrome 2
• A normal ferritin does not exclude hemochromatosis in younger patients—only ~70% of C282Y homozygotes have elevated ferritin early in disease 2
• Normal TS with elevated ferritin may still indicate iron overload in non-HFE hemochromatosis or compound heterozygotes 2

Treatment Pitfalls

• Overtreatment causes iron avidity, which mimics undertreatment with persistently elevated TS despite normal/low ferritin 3
• Do not delay phlebotomy for liver biopsy in confirmed C282Y homozygotes with elevated iron stores 4
• Phlebotomy prevents complications only when initiated before severe iron overload develops 7

Screening Limitations

• Population-wide screening is not recommended due to low penetrance (only 10% of C282Y homozygotes develop clinically significant organ damage) 5, 3
• Targeted case-finding is appropriate for: symptomatic patients, unexplained liver disease, first-degree relatives, and one-time screening of asymptomatic non-Hispanic white men 2, 5